Divi's Laboratories logo

Divi's Laboratories financials: balance sheet, profit and loss, cash flow

NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap

Divi's Laboratories Limited · Face value ₹2 · Listed Mar 2003
Last close ₹9,505.50up ₹455.50 (5.03%)BSE ₹9,478.00

Share price at the NSE close on 27 Oct 2026. Previous close ₹9,050.00.

27 Oct: open ₹9,090.00, high ₹9,505.50, low ₹9,067.00

52-week range of traded prices to 27 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
Market cap
₹2,52,341 Cr50th largest listed
P/E
86.27
P/B
15.06
Dividend yield
0.32%
ROE
18.4%
ROCE
20.8%
Debt to equity
0.00
Volume, NSE
8,02,78051.3% delivered

Divi's Laboratories' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Divi's Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
4,1061,060Mar 173,913877Mar 184,9461,353106Mar 195,3941,37734Mar 206,9691,9840.4Mar 218,9602,9600Mar 227,7681,8230Mar 237,8451,6000Mar 249,3602,1912Mar 2510,5602,5680Mar 26
Peak revenue ₹10,560 Cr, year to Mar 2026; lowest ₹3,913 Cr, year to Mar 2018

Operating and net margin, per cent

  • Operating margin
  • Net margin
43.3%20.4%35.2%32.2%37.8%33.8%41.0%43.3%30.5%28.1%31.7%32.6%25.8%22.4%27.3%25.5%28.5%33.0%23.5%20.4%23.4%24.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.0% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue10,560
  2. Materials and goods−4,093
  3. Employee costs−1,442
  4. Other expenses−1,584
  5. Operating profit3,441
  6. Depreciation−463
  7. Other income+507
  8. One-off items−74
  9. Finance costs−23
  10. Profit before tax3,388
  11. Tax−820
  12. Net profit2,568

What the company owns

  • Plant, investments and other assets₹9,681 Cr
  • Inventory₹3,954 Cr
  • Cash and bank₹3,414 Cr
  • Receivables₹2,984 Cr

What pays for it: net worth and liabilities

  • Net worth₹16,761 Cr
  • Other liabilities₹2,061 Cr
  • Owed to suppliers₹1,211 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Divi's Laboratories quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 23 MayMar 2023Mar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 1 Aug
Revenue from operations4,1063,9134,9465,3946,9698,9607,7687,8459,36010,56011,230
2,6602,6513,0743,5724,1095,0785,4005,6406,3927,1197,263
Materials and goods bought1,5341,5341,8252,1092,3242,9673,0543,1293,7254,0934,123
Employee costs4694565426218269469751,0941,2431,4421,510
Other expenses6576617078439601,1651,3711,4171,4241,5841,630
Operating profit before depreciation1,4461,2621,8721,8222,8603,8822,3682,2052,9683,4413,967
Operating margin35.2%32.2%37.8%33.8%41.0%43.3%30.5%28.1%31.7%32.6%35.3%
Materials, % of revenue37.4%39.2%36.9%39.1%33.3%33.1%39.3%39.9%39.8%38.8%36.7%
Employee costs, % of revenue11.4%11.7%11.0%11.5%11.8%10.6%12.6%13.9%13.3%13.7%13.4%
Other expenses, % of revenue16.0%16.9%14.3%15.6%13.8%13.0%17.6%18.1%15.2%15.0%14.5%
Depreciation and amortisation123142169186256312343378402463484
Operating profit after depreciation1,3231,1191,7031,6362,6043,5702,0251,8272,5662,9783,483
Other income7511315619063114345339352507452
Finance costs2146111322326
Profit before one-off items and tax1,3951,2311,8551,8192,6663,6842,3692,1632,9163,4623,909
One-off items000000000−74−74
Profit before tax1,3951,2311,8551,8192,6663,6842,3692,1632,9163,3883,835
335354502443682723545563725820910
Net profit1,0608771,3531,3771,9842,9601,8231,6002,1912,5682,925
Other comprehensive income––000412032120
Total comprehensive income––1,3521,3771,9852,9651,8351,6002,1942,5892,945
Net margin25.8%22.4%27.3%25.5%28.5%33.0%23.5%20.4%23.4%24.3%26.0%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Filed 23 MayMar 2023Mar 2024Mar 2025Mar 2026
6,9577,3109,29511,72812,76713,57114,96916,761
Share capital5353535353535353
Reserves6,9047,2579,24211,67512,71413,51814,91616,708
Borrowings10634000020
8479271,1121,1961,1011,2781,4522,043
2342993674515716215111,229
Total assets8,0388,53610,77413,37514,43915,47016,93220,033
3,3883,8564,5995,0235,1275,7956,8518,937
4,6504,6806,1758,3529,3129,67510,08111,096
Net debt−1,408−1,060−2,156−2,819−4,213−3,980−3,713−3,414
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Filed 23 MayMar 2023Mar 2024Mar 2025Mar 2026
1,9471,9122,4601,2611,6532,738
2,5912,5532,9321,6372,4773,600
−264−1,372419−607−556100
Receivables−265−742650−361−582−141
Inventories−281−683−172−184−52−718
Payables17534−346295294
Other working capital10818−25−124−17665
Tax paid−644−641−473−376−824−862
Capital spending9107134731,0031,4382,520
Free cash flow1,0371,1991,987258215218
75−2,195−2,708−269−804−2,219
−35−532−797−799−799−804
Dividends paid0531796796796797
Shares bought back000000
Shares issued000000
Net change in cash1,987−816−1,04519350−285
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Divi's Laboratories dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 23 MayMar 2023Mar 2024Mar 2025Mar 2026
Earnings per share₹39.95₹33.04₹50.96₹51.85₹74.75₹111.52₹68.69₹60.27₹82.53₹96.75
Diluted earnings per share₹39.95₹33.04₹50.96₹51.85₹74.75₹111.52₹68.69₹60.27₹82.53₹96.75
Dividend per share₹10.00₹10.00₹16.00₹16.00₹20.00₹30.00₹30.00₹30.00₹30.00₹30.00
Book value per share––₹262.09₹275.38₹350.15₹441.82₹480.96₹512.11₹564.87₹632.49
Dividend payout25.0%30.3%31.4%30.9%26.8%26.9%43.7%49.7%36.3%31.0%
Shareholder yield––––0.0%0.5%1.1%0.9%0.5%0.5%
Market cap at the year end (₹ crore)16,56128,94145,21252,80396,1741,16,86174,95191,4621,53,3201,57,874

Ratios

Consolidated, years to March.Divi's Laboratories PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 23 MayMar 2023Mar 2024Mar 2025Mar 2026
Revenue growth8.7%−4.7%26.4%9.1%29.2%28.6%−13.3%1.0%19.3%12.8%
Operating profit growth2.1%−12.7%48.4%−2.7%57.0%35.7%−39.0%−6.9%34.6%15.9%
Net profit growth−4.6%−17.3%54.2%1.8%44.2%49.2%−38.4%−12.3%36.9%17.2%
Earnings per share growth−4.6%−17.3%54.2%1.7%44.2%49.2%−38.4%−12.3%36.9%17.2%
––19.4%19.3%23.9%28.2%14.9%12.1%15.4%16.2%
–––−0.1 pts4.6 pts4.3 pts−13.3 pts−2.7 pts3.2 pts0.8 pts
From the net margin–––−1.3 pts2.2 pts3.8 pts−8.2 pts−2.0 pts1.8 pts0.6 pts
From asset turnover–––1.0 pts2.3 pts0.8 pts−4.9 pts−0.8 pts1.4 pts−0.2 pts
From borrowing–––0.1 pts0.0 pts−0.3 pts−0.2 pts0.0 pts0.0 pts0.4 pts
Return on capital employed––24.1%22.3%28.0%30.4%15.9%13.5%17.1%17.8%
Cash conversion––––98.1%64.6%134.9%78.8%75.4%106.6%
Interest cover587.9841.5486.6268.22,993.54,463.03,021.9609.01,283.0129.5
Debt to equity––0.020.000.000.000.000.000.000.00
Receivable days––8696889984100106103
Inventory days––354323337348359371317353
Payable days––9810212098919689108
Cash conversion cycle, days––342316305349352376334348
Working capital days––177182152177188206192195
Asset turnover––0.620.650.720.740.560.520.580.57
Assets per rupee of net worth––1.161.161.161.151.141.141.141.17
Sales per rupee of plant––2.371.951.882.081.651.661.721.62
Capital spending to depreciation––––3.562.291.382.653.585.44
Plant being built, % of plant in use––23.6%33.2%19.2%10.9%4.5%16.4%18.8%32.4%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
13.9%
Cash from operations against operating profit
79.6%
Measure10 years5 years3 years
Revenue growth, yearly rate10.8%8.7%10.8%
Profit growth, yearly rate8.7%5.3%12.1%
Return on equity, average–17.3%14.6%
Return on capital employed, average–18.9%16.1%
Operating margin, average34.6%33.2%30.8%
Net margin, average25.4%24.9%22.7%
Asset turnover, average–0.590.56
Cash conversion cycle, days, average–352353
Interest cover, average1,468.41,901.3673.8
Debt to equity, average–0.000.00

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations10,0245,6522,738
Cash from investing−8,195−3,292−2,219
Cash from financing−3,732−2,402−804
Capital spending6,1474,9612,520
Dividends paid3,7162,389797
Shares bought back000
Shares issued for cash000
Borrowings raised000
Borrowings repaid000

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––775367
Altman Z-scorePublished threshold 1.81––28.2428.9042.2346.0229.8931.6949.7531.70
Beneish M-scorePublished threshold −1.78––––−2.43−1.87−3.09−1.54−1.98−2.31
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−0.3926.8614.894.078.2811.09
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.930.880.960.89
Receivables growth less revenue growthOur threshold 0 percentage points–––12.43−10.5816.02−12.7419.287.36−3.56
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−10.364.874.193.163.65−17.4112.31
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.00−1.600.930.330.630.473.27
Assets under construction, years of additionsOur threshold 2 years of additions–––1.050.600.510.291.960.921.37
Effective tax ratePublished threshold 17.16 per cent24.0028.7827.0824.3425.5719.6323.0226.0324.8624.20
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––2.233.078.65−3.40−1.24
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 Sep 2026CARE Ratings LimitedNon-fund-based - LT/ ST-BG/LCCARE AA+ / CARE A1+Review, Re-affirmStable485
7 Sep 2026CARE Ratings LimitedFund-based - LT-Cash CreditCARE AA+Review, Re-affirmStable30
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.